<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128050</url>
  </required_header>
  <id_info>
    <org_study_id>NS-SICH-2005</org_study_id>
    <nct_id>NCT00128050</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)</brief_title>
  <acronym>PRE-SICH</acronym>
  <official_title>Efficacy and Safety of Factor VIIa (Eptacog Alfa) on Rebleeding After Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage. A Randomized, Controlled, Open-Label, Investigator-Blinded Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the role of surgical treatment is still controversial, surgical evacuation of
      intracerebral hematoma is a frequent practice. Rebleeding is a frequent complication in
      patients submitted to hematoma evacuation. It has been reported that smaller postoperative
      volume of hematoma is associated with a better outcome. The investigators hypothesize that
      the administration of Factor VIIa (Eptacog alfa) immediately after surgical evacuation of the
      hematoma can reduce postoperative rebleeding.

      Aims of the Study:

      This study will investigate:

        1. The efficacy of Eptacog alfa in preventing or reducing rebleeding after surgery for
           spontaneous supratentorial ICH; and

        2. The safety of product administration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is the evaluation of efficacy of Factor VIIa (Eptacog alfa, NovoSeven,
      Novo Nordisk) on rebleeding after surgery for primary supratentorial ICH. All patients
      included in the study will perform a CT scan within 3 hours before surgery, then immediately
      after surgery, and 18-30 hours after surgery. The hematoma volume will be evaluated by a
      multi-slice CT scan. All CT scan images will be sent to the Coordinating Center where the
      hematoma volume will be evaluated by a dedicated software by the same investigator who will
      be unaware of the treatment (investigator- blinded study).

      SAFETY EVALUATION:

      Seventeen episodes of thrombotic spontaneous adverse events have been reported after
      administration of 480,000 standard doses of Eptacog alfa in hemophilic patients. These
      episodes include myocardial infarction, acute cerebrovascular thrombosis, disseminated
      intravascular coagulation (DIC), deep venous thrombosis (DVT) and pulmonary embolism.

      Before and after hematoma removal will be evaluated ECG, myocardiac enzymes, coagulation
      profile, CT scan (looking for ischemic events) and venous echodoppler ultrasound of lower
      extremities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of Factor VIIa (Eptacog alfa) in preventing or reducing rebleeding after surgery for spontaneous supratentorial ICH</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of product administration</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with recombinant FVIIa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFactor VIIa (Eptacog alfa, NovoNordisk)</intervention_name>
    <description>rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFVIIa</intervention_name>
    <description>Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodiun chloride 0.9%</intervention_name>
    <description>Bolus injection of sodium chloride 0.9% after surgical hematoma removal</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-75 years inclusive

          -  Intraparenchymal primary supratentorial intracerebral hemorrhage requiring surgical
             evacuation

          -  Any Glasgow Coma Score (GCS) score

          -  Surgery expected to be performed within 24 hours from symptoms onset

        Exclusion Criteria:

          -  Age below 18

          -  Intraparenchymal hematoma secondary to rupture of cerebral aneurysm or bleeding of
             arteriovenous (A-V) malformation or cerebral tumors

          -  Contemporary involvement in another study

          -  Pregnancy

          -  Myocardial infarction in the six months preceding enrolment

          -  Coronary or carotid stents positioned in the six months preceding enrolment

          -  Solid organ transplant patients (e.g., heart, lung, liver, kidney)

          -  Pregnancy

          -  Myocardial infarction in the six months preceding enrolment

          -  Coronary and carotid stents positioned in the six months preceding enrolment

          -  Solid organ transplant patients (e.g., heart, lung, liver, kidney)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Imberti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico S. Matteo - Pavia - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Maggiore della Carit√†&quot;</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II Dpt Anesthesiology&amp;Critical Care Medicine - IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Morgenstern LB, Demchuk AM, Kim DH, Frankowski RF, Grotta JC. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology. 2001 May 22;56(10):1294-9.</citation>
    <PMID>11376176</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Roberto Imberti, M.D.</name_title>
    <organization>Fondazione IRCCS Policlinico S. Matteo</organization>
  </responsible_party>
  <keyword>Spontaneous intracerebral hemorrhage</keyword>
  <keyword>ICH</keyword>
  <keyword>intracerebral rebleeding</keyword>
  <keyword>cerebral hematoma evacuation</keyword>
  <keyword>cerebral hematoma volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 11, 2010</submitted>
    <returned>June 9, 2010</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

